Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Lactobacillus rhamnosus GG (LGG) is a clinically-studied probiotic strain that strengthens intestinal barrier function through adhesion proteins and bacteriocin production. LGG modulates immune responses via Toll-like receptor pathways and produces beneficial metabolites that support digestive and immune health.
Reported Benefits (Provisional)
Origin & History
Lactobacillus rhamnosus GG (LGG) is a well-researched probiotic strain derived from human intestinal microbiota. It is produced through fermentation and is commonly used in dietary supplements and functional foods.
Research Narrative (Provisional)
Lactobacillus rhamnosus GG has been extensively studied, with numerous RCTs demonstrating its efficacy in supporting gut health and immune function. Meta-analyses confirm its benefits in various health conditions.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
- Contains live probiotic cultures. - Produces lactic acid, supporting gut health. - Rich in bioactive compounds that modulate the immune system.
Reported Mechanism (Provisional)
LGG adheres to intestinal epithelial cells via pili proteins, strengthening tight junctions and preventing pathogen colonization. The strain produces bacteriocins and short-chain fatty acids (SCFAs) that inhibit harmful bacteria while stimulating beneficial microbiota growth. LGG activates dendritic cells and modulates cytokine production through Toll-like receptor 2 (TLR2) signaling, enhancing both innate and adaptive immune responses.
Clinical Narrative (Provisional)
Over 800 published studies support LGG's efficacy, with randomized controlled trials involving more than 15,000 participants. Clinical research demonstrates 40-60% reduction in antibiotic-associated diarrhea duration and 25% decrease in respiratory infection frequency in children. Meta-analyses show significant benefits for acute gastroenteritis recovery, with symptom duration reduced by 0.7-1.2 days. Evidence strength is considered high for digestive applications and moderate for immune support, with most studies using 1-10 billion CFU daily dosing.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.